PMID- 32612352
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20210604
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 14
DP  - 2020
TI  - Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, 
      and Place in Therapy.
PG  - 2487-2501
LID - 10.2147/DDDT.S221093 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is an emerging epidemic in Asian countries, 
      especially in India. With the advent of the SGLT2 inhibitor class of drugs 
      demonstrating benefits beyond glycemic control, viz. weight loss, blood pressure 
      reduction, and cardiovascular and renal protection, the management of T2DM has 
      taken a quantum leap. Remogliflozin etabonate (RE) is the latest addition to the 
      SGLT2 inhibitor class of drugs that have been recently approved in India for the 
      management of T2DM. RE is a potent and selective inhibitor of SGLT2 with the 
      unique distinction of being administered as a prodrug, existence of active 
      metabolites, and short half-life necessitating twice-daily dosing. The Phase III 
      study of RE demonstrated it to be an efficacious and safe agent and non-inferior 
      to the currently available SGLT2 inhibitors. This paper reviews not only the 
      pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile of RE 
      but also its molecular and clinical development program. This review has taken 
      into consideration all available published as well as unpublished literature on 
      RE and discusses the individual studies performed during its development for 
      characterization of pharmacological profile.
CI  - (c) 2020 Mohan et al.
FAU - Mohan, Viswanathan
AU  - Mohan V
AD  - Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialties Centre, 
      Chennai, Tamil Nadu, India.
FAU - Mithal, Ambrish
AU  - Mithal A
AD  - Endocrinology and Diabetology, Max Healthcare Hospital, Gurgaon, India.
FAU - Joshi, Shashank R
AU  - Joshi SR
AD  - Joshi Clinic, Lilavati Hospital, Apollo Sugar Clinic and Bhatia Hospital, Mumbai, 
      India.
FAU - Aravind, S R
AU  - Aravind SR
AUID- ORCID: 0000-0001-7631-8777
AD  - Diacon Hospital, Bengaluru, India.
FAU - Chowdhury, Subhankar
AU  - Chowdhury S
AD  - Deptartment of Endocrinology, IPGME&R and SSKM Hospital, Kolkata, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200624
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pyrazoles)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - TR0QT6QSUL (remogliflozin etabonate)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - *Drug Development
MH  - Glucosides/chemical synthesis/chemistry/*pharmacology
MH  - Humans
MH  - Hypoglycemic Agents/chemical synthesis/chemistry/*pharmacology
MH  - Pyrazoles/chemical synthesis/chemistry/*pharmacology
MH  - Sodium-Glucose Transporter 2/metabolism
MH  - Sodium-Glucose Transporter 2 Inhibitors/chemical 
      synthesis/chemistry/*pharmacology
PMC - PMC7322139
OTO - NOTNLM
OT  - SGLT2 inhibitor
OT  - T2DM
OT  - design
OT  - development
OT  - etabonate
OT  - place in therapy
OT  - remogliflozin
COIS- Dr. Viswanathan Mohan and all other authors of this manuscript report personal 
      fees as an Advisory Board Member of Glenmark Pharmaceuticals which markets 
      Remogliflozin in India, outside the submitted work. The authors report no other 
      conflicts of interest in this work.
EDAT- 2020/07/03 06:00
MHDA- 2021/06/05 06:00
PMCR- 2020/06/24
CRDT- 2020/07/03 06:00
PHST- 2020/01/04 00:00 [received]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
PHST- 2020/06/24 00:00 [pmc-release]
AID - 221093 [pii]
AID - 10.2147/DDDT.S221093 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2020 Jun 24;14:2487-2501. doi: 10.2147/DDDT.S221093. 
      eCollection 2020.